Építés alatt – nem éles oldal
Belépés
Visszavonva1. fázis

Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)

A legfontosabb adatok

Ki végzi
University of California, Davis
Hol
Sacramento (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
1. fázis
Kezdés
2024. júl.
Befejezés
2026. máj.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Aminolevulinic Acid
A regiszteradat frissítve
2024. augusztus 15.
Miért állt le
PI choice.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (16)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Histological confirmation of any subtype of primary Grades 2 or 3 soft tissue sarcomas (STS), per biopsy evaluation by a pathologist, according to Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
  • Treatment decision includes planned surgical resection of STS
  • Age ≥18 years at time of consent
  • ECOG Performance Status 0 - 1 (see Appendix)
  • Hematology and blood chemistry parameters defined by:; Leukocytes ≥ 3 × 109/L; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L, transfusions may be used to raise platelets to ≥ 100 × 109/L (no washout required); Hemoglobin ≥ 9 g/dL, transfusions may be used to raise Hgb to ≥ 9 g/dL (no washout required); Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); Aspartate transaminase (AST) / alanine transaminase (ALT) ≤ 2.5 × institutional ULN; Creatinine within normal institutional limits OR creatinine clearance ≥ 30 mL/min/1.73 m2 for patients with creatinine above institutional ULN
  • Participants of reproductive potential must agree to using adequate contraception (e.g., hormonal or barrier method of birth control; abstinence, an intrauterine device) for the duration of study participation (including dosing interruptions) and up to 42 days after end of study intervention; or be surgically sterilized (e.g., hysterectomy, tubal ligation, or vasectomy)
  • Ability to swallow study agent
  • Ability to understand and willingness to sign an informed consent form
  • Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study

Ki nem vehet részt

  • Uncontrolled, known concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness
  • Patient has had chemotherapy, tumor resection, or radiation treatment ≤ 21 days prior to surgery
  • Planned use of other potentially phototoxic substances (e.g., St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones and tetracyclines), and topical preparations containing aminolevulinic acid (5-ALA) for 24 hours during the perioperative period (defined as 24 hours prior to surgery to up to 24 hours post surgery)
  • Any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial
  • Acute/chronic forms of porphyria
  • Simultaneous participation in another clinical trial ≤ 21 days of enrollment or during the duration of the study period
  • Pregnant or planning to become pregnant during study participation or breastfeeding

Helyszínek itt: Egyesült Államok

  • University of California Davis Comprehensive Cancer CenterSacramento, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This will be a prospective pilot study that will evaluate 20 patients who were diagnosed with FNCLCC Grade 2 or 3 soft tissue sarcomas and will undergo surgical resection. Based upon the FDA label, successful protocols used for intraoperative fluorescence-guided visualization for glioma resections, and on drug company current dosing recommendation for this study, patients will be administered 20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgery. The use of 5-ALA fluorescence will be relevant for evaluating the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.

A vizsgálat csoportja

  • Aminolevulinic acid (5-ALA)A vizsgált kezelés

    20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgical resection. 5-ALA fluorescence will be used to evaluate the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.

    Kezelés: Aminolevulinic Acid

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. augusztus 15.